Anti-Spike RBD Antibody (CR3022) is an antibody specifically targeting and binding to coronavirus S protein. It showed excellent and significantly better activity in coronaviruses diseases. MW :150 KD.

Anti-Spike RBD Antibody (CR3022) is an antibody specifically targeting and binding to coronavirus S protein. It showed excellent and significantly better activity in coronaviruses diseases. MW :150 KD.

Anti-Spike S1 Antibody (NCOV-S1P14-Fc) is a mouse immunized antibody, targeting specific SARS-CoV-2 Spike protein RBD domain. It can be paired with other Anti-SARS-CoV-2 Spike S1 antibodies to detect SARS-CoV-2 Spike S1 protein. MW :80 KD.

Anti-Spike S1 Antibody (NCOV-S1P14-Fc) is a mouse immunized antibody, targeting specific SARS-CoV-2 Spike protein RBD domain. It can be paired with other Anti-SARS-CoV-2 Spike S1 antibodies to detect SARS-CoV-2 Spike S1 protein. MW :80 KD.

Anti-Spike S1 Antibody (NCOV-S1P14-Fc) is a mouse immunized antibody, targeting specific SARS-CoV-2 Spike protein RBD domain. It can be paired with other Anti-SARS-CoV-2 Spike S1 antibodies to detect SARS-CoV-2 Spike S1 protein. MW :80 KD.

Anti-STOP1 is a human monoclonal antibody against stable tubule-only polypeptides (STOP), a protein responsible for microtubule cold stabilization. MW: 145.78 KD.

Anti-STOP1 is a human monoclonal antibody against stable tubule-only polypeptides (STOP), a protein responsible for microtubule cold stabilization. MW: 145.78 KD.

Anti-STOP1 is a human monoclonal antibody against stable tubule-only polypeptides (STOP), a protein responsible for microtubule cold stabilization. MW: 145.78 KD.

Anti-TAT226 is a monoclonal antibody that binds to TAT226 with potential anti-tumor activity. MW: 144.66 KD.

Anti-TAT226 is a monoclonal antibody that binds to TAT226 with potential anti-tumor activity. MW: 144.66 KD.

Anti-TAT226 is a monoclonal antibody that binds to TAT226 with potential anti-tumor activity. MW: 144.66 KD.

Anti-TBFbR2 is a monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity. MW : 145.5 KD 

Anti-TBFbR2 is a monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity. MW : 145.5 KD 

Anti-TBFbR2 is a monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity. MW : 145.5 KD 

Anti-TCR is a monoclonal antibody targeting TCR. MW : 145.5 KD.

Anti-TCR is a monoclonal antibody targeting TCR. MW : 145.5 KD.

Anti-TCR is a monoclonal antibody targeting TCR. MW : 145.5 KD.

Anti-TCR (NKTT320) is a novel humanized monoclonal antibody specificly targeting for the invariant TCR. It is used use in cell-based cancer immunotherapy. MW :146.14 KD.

Anti-TCR (NKTT320) is a novel humanized monoclonal antibody specificly targeting for the invariant TCR. It is used use in cell-based cancer immunotherapy. MW :146.14 KD.

Anti-TCR (NKTT320) is a novel humanized monoclonal antibody specificly targeting for the invariant TCR. It is used use in cell-based cancer immunotherapy. MW :146.14 KD.

Anti-TEM7R / PLXDC2 is a humanized IgG1 monoclonal antibody against PLXDC1 (tumor endothelial marker 7 or TEM7), a cell-surface receptor for PEDF, with anti-tumor activity. MW: 143.94 KD.

Anti-TEM7R / PLXDC2 is a humanized IgG1 monoclonal antibody against PLXDC1 (tumor endothelial marker 7 or TEM7), a cell-surface receptor for PEDF, with anti-tumor activity. MW: 143.94 KD.

Anti-TEM7R / PLXDC2 is a humanized IgG1 monoclonal antibody against PLXDC1 (tumor endothelial marker 7 or TEM7), a cell-surface receptor for PEDF, with anti-tumor activity. MW: 143.94 KD.

Anti-TfR (Jr-141), is an antibody targeting human transferrin receptor (hTfR). It can be used in treatment of patients with mucopolysaccharidosis II (MPS II) and CNS disorders. MW :146.02 KD.

Anti-TfR (Jr-141), is an antibody targeting human transferrin receptor (hTfR). It can be used in treatment of patients with mucopolysaccharidosis II (MPS II) and CNS disorders. MW :146.02 KD.

Anti-TfR (Jr-141), is an antibody targeting human transferrin receptor (hTfR). It can be used in treatment of patients with mucopolysaccharidosis II (MPS II) and CNS disorders. MW :146.02 KD.

Anti-TGFb1 (M7824) is a bifunctional monoclonal antibody targeting programmed death ligand 1 (PD-L1) and transforming growth factor beta 1 (TGFb1). It exhibits anti-tumor efficacy against breast and colon carcinomas.

Anti-TGFb1 (M7824) is a bifunctional monoclonal antibody targeting programmed death ligand 1 (PD-L1) and transforming growth factor beta 1 (TGFb1). It exhibits anti-tumor efficacy against breast and colon carcinomas.

Anti-TGFb1 (M7824) is a bifunctional monoclonal antibody targeting programmed death ligand 1 (PD-L1) and transforming growth factor beta 1 (TGFb1). It exhibits anti-tumor efficacy against breast and colon carcinomas.

Anti-TGFb1 (NIS793) is a monoclonal antibody targeting TGF-β. It can be used in metastatic melanoma and non-small cell-lung cancer. MW :143.78 KD

Anti-TGFb1 (NIS793) is a monoclonal antibody targeting TGF-β. It can be used in metastatic melanoma and non-small cell-lung cancer. MW :143.78 KD

Anti-TGFb1 (NIS793) is a monoclonal antibody targeting TGF-β. It can be used in metastatic melanoma and non-small cell-lung cancer. MW :143.78 KD

Anti-TGFb1 (SRK181) is a monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 with potential antineoplastic activity. MW : 150 kD.

Anti-TGFb1 (SRK181) is a monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 with potential antineoplastic activity. MW : 150 kD.

Anti-TGFb1 (SRK181) is a monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 with potential antineoplastic activity. MW : 150 kD.

Anti-TIE2 / CD202b is a fully human monoclonal antibody that binds to human Tie2 and blocks the interaction between Tie2 or Tie2 ligands (angiopoietin). It has the potential to treat angiogenesis disorders. MW: 146.6 KD.

Anti-TIE2 / CD202b is a fully human monoclonal antibody that binds to human Tie2 and blocks the interaction between Tie2 or Tie2 ligands (angiopoietin). It has the potential to treat angiogenesis disorders. MW: 146.6 KD.

Anti-TIE2 / CD202b is a fully human monoclonal antibody that binds to human Tie2 and blocks the interaction between Tie2 or Tie2 ligands (angiopoietin). It has the potential to treat angiogenesis disorders. MW: 146.6 KD.

Anti-TLR3 / CD283 (CNTO5429) is a novel antibody that binds to the extracellular domain of TLR3 and inhibit poly(I:C)-induced inflammation. MW: 145.3 KD.

Anti-TLR3 / CD283 (CNTO5429) is a novel antibody that binds to the extracellular domain of TLR3 and inhibit poly(I:C)-induced inflammation. MW: 145.3 KD.

Anti-TLR3 / CD283 (CNTO5429) is a novel antibody that binds to the extracellular domain of TLR3 and inhibit poly(I:C)-induced inflammation. MW: 145.3 KD.

Anti-TLR7 is a monoclonal antibody against Toll-like receptor 7 (TLR7) with the potential to treat autoimmune disease. MW: 145.04 KD.

Anti-TLR7 is a monoclonal antibody against Toll-like receptor 7 (TLR7) with the potential to treat autoimmune disease. MW: 145.04 KD.

Anti-TLR7 is a monoclonal antibody against Toll-like receptor 7 (TLR7) with the potential to treat autoimmune disease. MW: 145.04 KD.

Anti-TMEFF1 / Tomoregulin-1 is a monoclonal antibody against TMEFF1 (a transmembrane protein with EGF-like and two Follistatin-like domains, Tomoregulin 1), a type I transmembrane glycoprotein. MW: 146.08 KD.

Anti-TMEFF1 / Tomoregulin-1 is a monoclonal antibody against TMEFF1 (a transmembrane protein with EGF-like and two Follistatin-like domains, Tomoregulin 1), a type I transmembrane glycoprotein. MW: 146.08 KD.

Anti-TMEFF1 / Tomoregulin-1 is a monoclonal antibody against TMEFF1 (a transmembrane protein with EGF-like and two Follistatin-like domains, Tomoregulin 1), a type I transmembrane glycoprotein. MW: 146.08 KD.

Anti-TMEFF2 is a human monoclonal anti-TMEFF2 antibody with potential anti-tumor activity. MW: 144.08 KD.

Anti-TMEFF2 is a human monoclonal anti-TMEFF2 antibody with potential anti-tumor activity. MW: 144.08 KD.

Anti-TMEFF2 is a human monoclonal anti-TMEFF2 antibody with potential anti-tumor activity. MW: 144.08 KD.